Comparing Ropivacaine Adductor Canal Blockade by Surgeon Versus Anesthesiologist

A Randomized Controlled Trial Comparing Intraoperative Surgeon-Performed Versus Anesthesiologist-Performed Adductor Canal Blockade After Primary Total Knee Arthroplasty

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03864588

Enrollment

164

Registered

2019-03-06

Start date

2018-10-01

Completion date

2019-09-30

Last updated

2019-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative, Satisfaction

Brief summary

The purpose of this study is to evaluate the efficacy of two methods of administering an adductor canal block (ACB) following total knee arthroplasty (TKA); intraoperative surgeon performed intra-articular adductor canal block (IACB) and anesthesiologist ultrasound guided ADC in the post-anesthesia recovery unit (PACU).

Interventions

DRUGRopivacaine

For primary TKA, Ropivacaine is used in both arms, either performed intra-operatively by surgeon or post-operatively (ultrasound guided) by anesthesiologist.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Patients undergoing unilateral primary TKA with underlying diagnosis of osteoarthritis * ASA I - III * Spinal anesthesia * All patients will have cemented total knee utilizing a medial parapatellar approach with posterior stabilized or cruciate retaining implants. A tourniquet will be used in all cases. * Patients must be between 18 and 80 years of age. * Active and valid email address for the participant.

Exclusion criteria

* Allergy to anesthetics or study analgesic medications. * Contraindication to regional anesthesia * Non-english speaking * ASA IV or greater * Renal insufficiency with Cr \> 2.0 or hepatic failure * General or epidural anesthesia * Sensory/motor disorder involving the operative limb * Patients who consume preoperative opioids for pain control. * Pregnant women * Mentally disabled patients and patients with psychiatric disorders that would prevent them from properly understanding and evaluating an informed consent process. * Prisoners

Design outcomes

Primary

Measure	Time frame	Description
Change in visual analog scale pain score	Up to 6 weeks post-surgery	The primary end point is the patients' reported visual analogue pain score (VAS). 0-100mm scale

Secondary

Measure	Time frame	Description
Change in range of motion	up to 6 weeks post-surgery	Range of motion
Change in timed up and go	up to 6 weeks post-surgery	Timed up and go
Change in daily opioid consumption	up to 6 weeks post-surgery	daily opioid consumption

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026